Skip to content

PEP-1324: Glycemic Response Testing

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02037854
Enrollment
12
Registered
2014-01-16
Start date
2014-01-31
Completion date
Unknown
Last updated
2014-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glycemic Response

Brief summary

The purpose of this study is to assess whether food ingredient(s) affect glycemic and insulinemic responses.

Interventions

OTHERNutrient formulation

Sponsors

PepsiCo Global R&D
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject is 18-75 years of age * Subject is male or non-pregnant females, 18-75 years of age, inclusive * Subject has a body mass index (BMI) ≥ 20.0 and \< 35 kg/m² at screening (visit 1). * Subject has to be non-smoker. * Subject is willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial. * Subject is willing to maintain current dietary supplement use throughout the trial. On test days, subject agrees not to take any dietary supplements until dismissal from the GI labs. Failure to comply will result in a rescheduled test visit. * Subject has normal fasting serum glucose (\<7.0mmol/L capillary corresponding to whole blood glucose \<6.3mmol/L). * Subject is willing to abstain from alcohol consumption and avoid vigorous physical activity for 24 h prior to all test visits. * Subject has no health conditions that would prevent him from fulfilling the study requirements as judged by the Investigator on the basis of medical history. * Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator.

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
Incremental area under the blood glucose response cruve0-2 hours

Secondary

MeasureTime frame
peak blood glucose0-2 hours
peak insulin0-2 hours

Countries

Canada

Contacts

Primary ContactJanice Campbell
JCampbell@gilabs.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026